{"id":"ketamine-dexmeditomidine-admixure","safety":{"commonSideEffects":[{"rate":null,"effect":"Emergence reactions/dissociation"},{"rate":null,"effect":"Hypertension"},{"rate":null,"effect":"Tachycardia"},{"rate":null,"effect":"Bradycardia"},{"rate":null,"effect":"Hypotension"},{"rate":null,"effect":"Respiratory depression"}]},"_chembl":{"chemblId":"CHEMBL742","moleculeType":"Small molecule","molecularWeight":"237.73"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Ketamine blocks NMDA glutamate receptors to produce dissociative anesthesia and analgesia while maintaining airway reflexes. Dexmedetomidine acts as a selective alpha-2 adrenergic agonist to enhance sedation, reduce anxiety, and provide additional analgesia. The combination is used clinically to achieve balanced anesthesia with improved hemodynamic stability and reduced emergence reactions compared to ketamine alone.","oneSentence":"This admixture combines ketamine (an NMDA receptor antagonist) with dexmedetomidine (an alpha-2 adrenergic agonist) to provide dissociative anesthesia with sedation and analgesia.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:50:55.922Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Anesthesia induction and maintenance"},{"name":"Sedation in intensive care settings"}]},"trialDetails":[{"nctId":"NCT05948267","phase":"PHASE4","title":"The Effect of Ketamine - Dexmedetomidine Admixture (Ketodex) on Hemodynamic Stability During Anesthesia Induction in Adults.","status":"COMPLETED","sponsor":"Kasr El Aini Hospital","startDate":"2023-05-25","conditions":"The Effect of Ketamine - Dexmedetomidine Admixture (Ketodex) on Hemodynamic Stability","enrollment":120}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"ketamine- dexmeditomidine admixure","genericName":"ketamine- dexmeditomidine admixure","companyName":"Kasr El Aini Hospital","companyId":"kasr-el-aini-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This admixture combines ketamine (an NMDA receptor antagonist) with dexmedetomidine (an alpha-2 adrenergic agonist) to provide dissociative anesthesia with sedation and analgesia. Used for Anesthesia induction and maintenance, Sedation in intensive care settings.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}